UB-VV500 / Umoja Biopharma - LARVOL DELTA

A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - P1 | N=100 | Not yet recruiting | Sponsor: Umoja Biopharma

New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology

Preclinical development of UB-VV500, an in vivo potency-enhanced CAR T cell product targeting BCMA and GPRC5D for multiple myeloma (ASGCT 2026) - "In addition, UB-VV500 also encodes a Rapamycin- Activated Cytokine Receptor (RACRTM), designed to enable small-molecule controlled IL-2/IL- 15-like signaling within the transduced cells, promoting CAR T cell expansion and antitumor activity. Finally, UB- VV500 induced strong antitumor effects in vivo against OPM-2 tumor cells expressing either BCMA or GPRC5D, leading to tumor clearance and enhanced overall survival. Overall, these data support the clinical development of UB-VV500 as a therapeutic modality for MM."

CAR T-Cell Therapy • IO biomarker • Preclinical • Hematological Malignancies • Multiple Myeloma • GPRC5D • IL2